Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 6/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311465 | 0.84 | MEN1 (0.47) | ADORA1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL312895 | 0.75 | ADORA1 (0.42) | ADORA1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL22476350 | 0.73 | ADORA1 (0.58) | ADORA1MEN1KMT2APOLBHSD17B10 | |
| SCHEMBL4735176 | 0.72 | ADORA1 (0.43) | ADORA1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL311846 | 0.72 | ALDH1A1 (0.49) | ADORA1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL14547760 | 0.72 | ADORA1 (0.40) | ADORA1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL16546227 | 0.72 | ADORA1 (0.44) | ADORA1MEN1KMT2APOLBMAPT | |
| SCHEMBL7889654 | 0.71 | ADORA1 (0.40) | ADORA1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL9258260 | 0.71 | ADORA1 (0.40) | ADORA1MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL30974906 | 0.71 | DYRK1A (0.35) | ADORA1JAK1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015672-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES FOR SELECTIVELY TARGETING TUMOR CELLS WITH FR-ALPHA AND FR-BETA TYPE RECEPTORS | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-01-19 | — | — | US | disclosed |
| US-9481678-B2 | Substituted pyrrolo[2,3-D]dipyrimidines for selectively targeting tumor cells with FR-alpha and FR-beta type receptors | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160229857-A1 | SUBSTITUTED PYRROLO[2,3-D]DIPYRIMIDINES FOR SELECTIVELY TARGETING TUMOR CELLS WITH FR-ALPHA AND FR-BETA TYPE RECEPTORS | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2010117425-A1 | CERTAIN SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | BIOGEN IDEC MA INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-0576211-B1 | Process for the synthesis of 4-hydroxy-5-halopyrrolo 2,3-D pyrimidine intermediates | LILLY CO ELI (US) | 2001-08-22 | — | — | EP | disclosed |
| US-5426187-A | Process for the preparation of 4-hydroxy-5-substituted ethynylpyrrolo [2,3-d]pyrimidine intermediates | ELI LILLY AND COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| EP-0576211-A2 | Process for the synthesis of 4-hydroxy-5-halopyrrolo 2,3-D pyrimidine intermediates | ELI LILLY AND COMPANY (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5235053-A | Process for the synthesis of 4-hydroxy-5-halopyrrold[2,3-d]pyrimidine intermediates | ELI LILLY AND COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229857-A1 | SUBSTITUTED PYRROLO[2,3-D]DIPYRIMIDINES FOR SELECTIVELY TARGETING TUMOR CELLS WITH FR-ALPHA AND FR-BETA TYPE RECEPTORS | FOLR2, FOLR1, DHFR | ADORA1 151/4885MEN1 4564/4885KMT2A 2551/4885 |
| US-20170015672-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES FOR SELECTIVELY TARGETING TUMOR CELLS WITH FR-ALPHA AND FR-BETA TYPE RECEPTORS | FOLR2, FOLR1, DHFR | ADORA1 181/4885MEN1 4728/4885KMT2A 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.